Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study

por Lipton, RB, Manack, AN, Serrano, D, Buse, DC
Publicado 2013

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study

por Manack, AN, Serrano, D, Turkel, CC, Lipton, RB, Buse, DC
Publicado 2013

Defining the Differences Between Episodic Migraine and Chronic Migraine

por Katsarava, Zaza, Buse, Dawn C., Manack, Aubrey N., Lipton, Richard B.
Publicado 2011

Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention (AMPP) study

por Lipton, RB, Serrano, D, Kori, S, Cunanan, C, Manack, AN, Reed, ML, Buse, DC
Publicado 2013

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study

por Buse, DC, Serrano, D, Kori, S, Cunanan, C, Manack, AN, Reed, ML, Lipton, RB
Publicado 2013

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

por Blumenfeld, Andrew M., Stark, Richard J., Freeman, Marshall C., Orejudos, Amelia, Manack Adams, Aubrey
Publicado 2018

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

por Burstein, Rami, Blumenfeld, Andrew M., Silberstein, Stephen D., Manack Adams, Aubrey, Brin, Mitchell F.
Publicado 2020

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Mig...

por Mechtler, Laszlo, Saikali, Nicolas, McVige, Jennifer, Hughes, Olivia, Traut, Alexandra, Adams, Aubrey Manack
Publicado 2022

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disabil...

por Lipton, Richard B., Manack Adams, Aubrey, Buse, Dawn C., Fanning, Kristina M., Reed, Michael L.
Publicado 2016

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

por Matharu, Manjit, Halker, Rashmi, Pozo-Rosich, Patricia, DeGryse, Ronald, Manack Adams, Aubrey, Aurora, Sheena K.
Publicado 2017

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Blumenfeld, Andrew M., Patel, Atul T., Turner, Ira M., Mullin, Kathleen B., Manack Adams, Aubrey, Rothrock, John F.
Publicado 2020

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons

por Melo-Carrillo, Agustin, Strassman, Andrew M, Schain, Aaron J, Adams, Aubrey Manack, Brin, Mitchell F, Burstein, Rami
Publicado 2020

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials

por Blumenfeld, Andrew M., Knievel, Kerry, Manack Adams, Aubrey, Severt, Lawrence, Butler, Matthew, Lai, Hongxin, Dodick, David W.
Publicado 2021

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale

por Lipton, Richard B., Buse, Dawn C., Adams, Aubrey Manack, Varon, Sepideh F., Fanning, Kristina M., Reed, Michael L.
Publicado 2017

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

por Blumenfeld, Andrew M., Frishberg, Benjamin M., Schim, Jack D., Iannone, Ashley, Schneider, Gary, Yedigarova, Larisa, Manack Adams, Aubrey
Publicado 2021

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results

por Adams, Aubrey Manack, Serrano, Daniel, Buse, Dawn C, Reed, Michael L, Marske, Valerie, Fanning, Kristina M, Lipton, Richard B
Publicado 2015

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Rothrock, John F., Adams, Aubrey Manack, Lipton, Richard B., Silberstein, Stephen D., Jo, Esther, Zhao, Xiang, Blumenfeld, Andrew M.
Publicado 2019

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

por Lipton, Richard B., Hutchinson, Susan, Ailani, Jessica, Reed, Michael L., Fanning, Kristina M., Manack Adams, Aubrey, Buse, Dawn C.
Publicado 2019

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis

por Diener, Hans-Christoph, Dodick, David W., Lipton, Richard B., Manack Adams, Aubrey, DeGryse, Ronald E., Silberstein, Stephen D.
Publicado 2020

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine

por Silberstein, Stephen D., Diener, Hans-Christoph, Dodick, David W., Manack Adams, Aubrey, DeGryse, Ronald E., Lipton, Richard B.
Publicado 2020